Neumann, F. J. et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehy394 (2018).
[DOI: 10.1093/eurheartj/ehy394]
Thiele, H. et al. One-year outcomes after PCI strategies in cardiogenic shock. N. Engl. J. Med. 379, 1699–16710 (2018).
[DOI: 10.1056/NEJMoa1808788]
Lansky, A. et al. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet 392, 1117–1126 (2018).
[DOI: 10.1016/S0140-6736(18)31649-0]
Stone, G. W. et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet 392, P1530–P1540 (2018).
[DOI: 10.1016/S0140-6736(18)32283-9]
Vranckx, P. et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392, 940–949 (2018).
[DOI: 10.1016/S0140-6736(18)31858-0]
Thiele, H. et al. PCI strategies in patients with acute cyocardial infarction and cardiogenic shock. N. Engl. J. Med. 377, 2419–2432 (2017).
[DOI: 10.1056/NEJMoa1710261]
Wald, D. S. et al. Preventive angioplasty in myocardial infarction. N. Engl. J. Med. 370, 283 (2014).
[DOI: 10.1056/NEJMoa1301150]
Serruys, P. W. et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N. Engl. J. Med. 363, 136–146 (2010).
[DOI: 10.1056/NEJMoa1004130]
Byrne, R. A. et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur. Heart J. 36, 2608–2620 (2015).
[DOI: 10.1093/eurheartj/ehv203]
